Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies
NCT03642496Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2018
- Primary completion
- Aug 2020
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label trial of ET019002-T in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 6 more, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Maximum Tolerated Dose at 12 weeks, Tmax of serum cytokine levels at 12 weeks and 2 more. Status: unknown.
02
Drugs
ET019002-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT03642496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642496.